Pharmaceutical-grade cultivation and export from the Democratic Republic of Congo
Compliant Operations
Central Africa Advantage
Partnership Ready
Pioneering pharmaceutical-grade medical cannabis in Central Africa
SAER Sarl is establishing the Democratic Republic of Congo's premier medical cannabis cultivation and export operation, delivering pharmaceutical-grade products to international markets whilst maintaining the highest standards of regulatory compliance and ethical business practice.
To become the trusted partner for pharmaceutical companies and institutional investors seeking reliable, compliant, and cost-effective medical cannabis supply from Africa. We are committed to quality, transparency, and sustainable development that benefits our stakeholders and local communities.
Unwavering commitment to GACP, GMP, and international regulatory standards
Consistent, traceable, medical-grade products meeting international specifications
Open communication with buyers, investors, and regulatory authorities
ESG-aligned operations supporting local economic development
A comprehensive medical cannabis cultivation and export operation
SAER Sarl is developing a state-of-the-art controlled environment agriculture facility in the Democratic Republic of Congo for the cultivation, processing, and export of pharmaceutical-grade medical cannabis. The project encompasses all stages from cultivation to export-ready packaging, with full regulatory compliance throughout the value chain.
Securing all necessary licences and permits from DRC authorities (Ministry of Health, Environment, Interior)
Construction of controlled environment greenhouses/indoor facilities meeting GACP/GMP specifications
Achieving GACP, GMP, and ISO certifications from internationally recognised auditing bodies
Commencement of controlled cultivation with full traceability and quality assurance protocols
Establishing long-term supply contracts with pharmaceutical companies and licensed distributors
First pharmaceutical-grade export shipments to approved international markets
Scalable operations designed to meet growing international pharmaceutical demand
Competitive production costs whilst maintaining pharmaceutical-grade quality standards
Multi-year supply contracts providing revenue visibility and investor confidence
Committed to the highest international pharmaceutical standards
SAER Sarl operates under a comprehensive compliance framework aligned with international pharmaceutical regulations. Our certification roadmap ensures that all operations meet or exceed the requirements of target export markets including the European Union, Canada, Australia, and Israel.
In Process
In Process
Planned
In Process
Status: Application in process
Issuing Body: International certification body (to be confirmed)
Description: GACP certification ensures that medicinal cannabis cultivation follows best agricultural practices with controlled environments, documented procedures, and full traceability from seed to harvest. This standard is fundamental for pharmaceutical-grade production and regulatory compliance in target export markets.
Status: Facility design phase aligned with GMP requirements
Issuing Body: International GMP auditing authority (to be confirmed)
Description: GMP certification covers the post-harvest processing, packaging, storage, and quality control procedures required for pharmaceutical products. All primary processing activities including drying, packaging, and storage will be conducted in GMP-compliant facilities with validated procedures and environmental controls.
Status: Planned for implementation following operational commencement
Target Standards: ISO 9001 (Quality Management), ISO 14001 (Environmental Management)
Description: ISO certifications demonstrate systematic approach to quality management and environmental responsibility. These internationally recognised standards support continuous improvement and stakeholder confidence in our operations.
Status: Application and consultation process underway
Regulatory Bodies: Ministry of Health, Ministry of Environment, Ministry of Interior
Description: All cultivation, processing, and export activities require licences and permits from multiple DRC government authorities. We are working closely with relevant ministries to ensure full compliance with national regulations governing controlled substances, environmental protection, and export controls.
Status: Alignment review with target market requirements
Target Markets: European Union, Canada, Australia, Israel
Description: Export of medical cannabis requires compliance with both DRC export regulations and import requirements of destination countries. We are establishing procedures and documentation systems aligned with international narcotics control conventions and pharmaceutical import/export regulations for all target markets.
Why investors should engage with SAER Sarl
The global medical cannabis market is experiencing unprecedented growth, driven by expanding legalisation, pharmaceutical applications, and increasing patient acceptance. SAER Sarl is positioned to capitalise on this growth through strategic first-mover advantage in Central Africa's restrictive regulatory environment.
International pharmaceutical demand for medical cannabis continues to expand as more markets legalise and clinical applications broaden. Established producers in North America and Europe face capacity constraints, creating opportunity for new compliant suppliers.
The DRC's restrictive regulatory framework limits competition, providing significant barriers to entry. SAER Sarl's early positioning and regulatory relationships create sustainable competitive advantage in Central Africa's emerging medical cannabis sector.
Competitive African production costs combined with premium pharmaceutical-grade pricing create compelling margin potential. Long-term supply contracts provide revenue visibility and reduce commercial risk for investors.
Full commitment to GACP/GMP certification and international regulatory alignment reduces compliance risk and ensures access to premium pharmaceutical markets. Our compliance-first approach protects investor capital and reputation.
Professional operations and pharmaceutical-grade quality position SAER Sarl for partnerships with major pharmaceutical companies. Strategic partnerships provide validation, off-take security, and potential for accelerated growth.
Sustainable operations supporting local economic development and employment creation. Our commitment to environmental responsibility and social impact aligns with institutional investor ESG requirements and enhances investment attractiveness.
SAER Sarl is seeking strategic investors and partners to support facility development, certification processes, and operational commencement. We welcome inquiries from institutional investors, pharmaceutical companies, and strategic partners interested in participating in Central Africa's medical cannabis opportunity.
Request Investment InformationClear pathways for buyers and investors
Detailed financial projections, operational plans, and commercial terms are available to qualified parties under Non-Disclosure Agreement. We welcome comprehensive due diligence from serious buyers and investors.
Request NDAExperienced leadership driving SAER Sarl's vision
Founder & Chief Executive
Professor John Kasuku brings extensive experience in African agricultural development, international trade, and regulatory compliance to SAER Sarl. His deep understanding of Central African business environments and institutional relationships positions the company for successful navigation of the DRC's regulatory framework.
Professor Kasuku's commitment to pharmaceutical-grade quality, ethical business practice, and sustainable development guides SAER Sarl's mission to become Central Africa's trusted medical cannabis partner.
Contact: Available via contact form below
Connect with SAER Sarl for partnership opportunities
For pharmaceutical companies and licensed distributors interested in supply agreements
For institutional investors and strategic partners interested in investment opportunities
Request Non-Disclosure Agreement for access to detailed documentation
Société à Responsabilité Limitée
Democratic Republic of Congo
All inquiries will receive response within 48 hours